Clinical trials: Stem Cell Transplant
Perianal Fistula, Adipose Tissue
Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas
This study investigated the cellular and molecular characteristics of AT-MSCs obtained from autologous AT therapy in patients with high transphincteric perianal fistulas of crytoglandular origin.
- Conditions
- Perianal Fistula, Adipose Tissue, Tissue Transplantation
- Trial name
- NCT04834609
- Testing
- Injection of autologous adipose tissue in anal fistula
- Volunteers
- 27 people
- Sponsor
- University of Aarhus
Leukemia, Acute, MDS
Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT
This study is to explore the efficacy and safety of introduction of chidamide in PTCy based GVHD prophylaxis in patients undergoing allogeneic PBSCT.
- Trial name
- NCT03336632
- Testing
- Chidamide, Cyclophosphamide, cyclosporine A
- Where
- 2 sites in China
- Volunteers
- 50 people
- Sponsor
- Sichuan University
Lymphoid Leukemia, Acute, Myeloid Malignancy
T-cell Receptor α/β Depleted Donor Lymphocyte Infusion
This pilot study is being conducted to treat patients who have a certain type of malignancy (lymphoid or myeloid) with immune effector cells after a T-cell depleted allogeneic hematopoietic cell transplantation (TCD HSCT).
- Conditions
- Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
- Trial name
- NCT05350163
- Testing
- T-cell Receptor α/β Depleted Donor Lymphocyte Infusions
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Guenther Koehne
Micromastia
Grafting of Autologous Adipose Stromal Cell Trial
Grafting of autologous stromal cell trial is a prospective study comparing routine fat grafting versus stromal vascular fraction enriched fat grafting.
- Trial name
- GAASC (NCT02116933)
- Testing
- Adipose Derived Stem Cells, SVF Enriched Autologous Fat Grafting
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Tower Outpatient Surgical Center
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome
Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant
This randomized clinical trial studies different chemotherapies in treating patients with myelodysplastic syndrome before donor stem cell transplant.
- Conditions
- Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome
- Trial name
- ICT-HCT (NCT01812252)
- Testing
- Azacitidine (AZC), Decitabine, Quality-of-Life Assessment
- Where
- 4 sites in United States
- Volunteers
- 50 people
- Sponsor
- Fred Hutchinson Cancer Center
Crohn's Disease
Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment
The purpose of this study is to evaluate the safety and potential clinical benefit of lymphoablation followed by autologous HSCT rescue in therapy refractory Crohn's disease
- Trial name
- HSCT (NCT01932658)
- Testing
- Hematopoietic stem cell transplantation
- Where
- United States
- Sponsor
- University of California, Los Angeles
Multiple Myeloma and Plasma Cell Neoplasm
Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma
RATIONALE: Giving chemotherapy followed by treated T cells before a stem cell transplant stops the growth of cancer cells by stopping them from dividing or by killing them.
- Trial name
- NCT00938626
- Testing
- anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia
This phase I trial tests the safety, best dose, and effectiveness of revumenib given as maintenance therapy after standard hematopoietic stem cell transplant (HSCT) in patients with acute lymphoblastic leukemia, acute myeloid…
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Childhood Acute Lymphoblastic Leukemia, Childhood Acute Myeloid Leukemia
- Trial name
- NCT07498465
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Sponsor
- Children's Oncology Group
Acute-graft-versus-host Disease, Allogeneic Hematopoietic Stem Cell Transplantation
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplation
Primary Objective: It is hypothesized that the efficacy of Sitagliptin would reduce the incidence of grade II-IV acute Graft Versus Host Disease (GVHD) by day +100 post-transplant in patients undergoing alternative donor (related…
- Trial name
- SHIELD (NCT05149365)
- Testing
- Sitagliptin + Standard Prophylaxis, Standard Prophylaxis
- Where
- China
- Volunteers
- 190 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Exhaled Breath Condensate
"Exhaled Breath Condensate" in Allogeneic Stem Cell Recipients and the Value in Follow-up
The most effective treatment of hematologic malignancies and some benign hematological diseases is allogeneic stem cell transplantation therapy. Pulmonary complications can occur after allogeneic stem cell transplantation.
- Trial name
- NCT02318316
- Testing
- Exhaled breath condensate
- Volunteers
- 80 people
- Sponsor
- Gazi University
Chronic Granulomatous Disease
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide
Background: CGD causes infections and inflammation. The only cure currently is a bone marrow transplant. Most often a perfectly matched bone marrow donor is used.
- Trial name
- NCT03910452
- Testing
- Busulfan, Alemtuzumab, Cyclophosphamide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hematopoietic Stem Cell Transplantation, Hematologic Malignancy
αβT Cell/CD19+ B Cell Depletion for Alternative Donor Allogeneic Hematopoietic Cell Transplantation (HSCT)
This is a study utilizing the Magnetic-activated cell sorting (CliniMACS®) Alpha-Beta T-cell (αβT)/Cluster of Differentiation 19 (CD19), also called B lymphocyte antigen CD19 depletion device for Children and Young Adults with…
- Trial name
- TB19DHCT (NCT06082947)
- Testing
- CliniMACS®
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Nationwide Children's Hospital
Myeloproliferative Disorders, Acute Myelogenous Leukemia
Specialized Blood Cell Transplants for Cancers of the Blood and Bone Marrow
The are a variety of cancerous diseases of the blood and bone marrow that can be potentially cured by bone marrow transplantation (BMT).
- Conditions
- Myeloproliferative Disorders, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00003838
- Testing
- T-cell replete PBPC allograft, Methotrexate, Cyclosporine
- Where
- United States
- Volunteers
- 202 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
The reason for doing this study is to see if cancer will respond to immune therapy after transplantation of blood stem cells (from the bone marrow) using a new kind of treatment regimen that is less toxic than that previously…
- Trial name
- NCT00005851
- Testing
- fludarabine phosphate, total-body irradiation, nonmyeloablative allogeneic hematopoietic stem cell transplantation
- Where
- 6 sites in United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Center
Paediatric Patients Affected by Haematological Malignancies and Eligible to Undergo HSCT From an Unrelated Volunteer
Randomized Study of ATG for Graft Versus Host Disease (GVHD) Prevention in Paediatric Patients Given an Unrelated Donor Stem Cell Transplantation
Paediatric patients affected by haematological malignancies and eligible to undergo HSCT from an unrelated volunteer will be stratified according to the degree of compatibility with their donor, the source of haematopoietic stem…
- Trial name
- ATG FRES (NCT00934557)
- Testing
- ATG Fresenius
- Where
- Italy
- Volunteers
- 42 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia
Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant
This phase I/II trial studies the side effects of laboratory-treated T cells and to see how well they work in treating patients with high-risk acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelogenous…
- Conditions
- Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
- Trial name
- NCT01640301
- Testing
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
RATIONALE: Giving chemotherapy before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Trial name
- NCT01020734
- Testing
- anti-thymocyte globulin, busulfan, cyclophosphamide
- Where
- 2 sites in South Korea
- Volunteers
- 263 people
- Sponsor
- Asan Medical Center
Alpha Thalassemia Major, Hemoglobinopathy; With Thalassemia
In Utero Hematopoietic Stem Cell Transplantation for Alpha-thalassemia Major (ATM)
The investigators aims to evaluate the safety of in utero hematopoietic stem cell transplantation in fetuses with alpha-thalassemia major performed at the time of in utero transfusion of red blood cells.
- Conditions
- Alpha Thalassemia Major, Hemoglobinopathy; With Thalassemia, Hemoglobinopathies, Fetal Anemia
- Trial name
- NCT02986698
- Testing
- in utero hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of California, San Francisco
Multiple Myeloma
Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients
The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the…
- Trial name
- NCT00103662
- Testing
- Granulocyte colony-stimulating factor plus plerixafor
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 302 people
- Sponsor
- Genzyme, a Sanofi Company
Hematopoietic Stem Cell Transplantation, Haplo-identical Donor
Haplo HCT vs Haplo-cord HCT for Patients With AML
Patients who have acute myeloid leukemia and will undergo haplo-identical donor hematopoeitic cell transplantation (haplo HCT) are potential candidates of this trial.
- Conditions
- Hematopoietic Stem Cell Transplantation, Haplo-identical Donor, Cord Blood Unit, Acute Myeloid Leukemia
- Trial name
- NCT03719534
- Testing
- haplo-HCT, haplo-cord HCT
- Where
- 5 sites in China
- Volunteers
- 134 people
- Sponsor
- The First Affiliated Hospital of Soochow University